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Histon¢ H4 can be reversibly acetylated at lysine residues 5, 8, 12 and 16. It is possible that acetylation of individual 
residues will exert specific effects on chromatin function, but this hypothesis difficult o test with present techniques 
for analysis of acetylation. To address this problem, we have prepared antibodies which distinguish H4 molecules acetyl- 
ated at each of the sites used in vivo. By electrophoresis and immunolabeling we have shown that, in H4 from human 
cells, the four lysine residues are acetylated ina preferred, but not exclusive order, namely lysine 16, followed by 12 and 
8, followed by 5. 
Histone H4; Acetylation site; Synthetic peptide; Site-specific antibody; (HL60 cell) 
1. INTRODUCTION 
The core histones in eukaryotic ells are all sub- 
ject to cyclical, enzyme catalyzed acetylation and 
deacetylation at defined lysine residues [1]. This 
modif icat ion can influence chromatin structure [2] 
and evidence is accumulating that histones 
associated with actively transcribed genes are more 
highly acetylated than those from non-transcribed 
regions [3-5]. 
Histone H4 can be acetylated at up to four lysine 
residues in its amino-terminal domain. As this 
region is identical in most eukaryotic organisms 
[1], it seems probable that each residue has a defin- 
ed and significant role and that modif ication of  
particular lysines by acetylation will exert specific 
effects on chromatin structure and function. 
However,  it has proved difficult to test this 
possibility because, until recently, identification of  
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specific acetylated lysines has required sequencing 
and/or  peptide analysis [6,7], techniques which re- 
quire purified material f rom relatively large 
numbers of  cells. We have attempted to develop an 
alternative approach more suited to functional 
studies by preparing antibodies which recognise 
H4 molecules acetylated at specific sites [8]. In this 
publication we describe antisera which distinguish 
H4 molecules acetylated at each one of  the four 
possible sites. These antisera have enabled us to 
define the order in which these sites are used in 
human cells. 
2. MATERIALS  AND METHODS 
2.1. Preparation of antisera 
Peptides were prepared by the University of Birmingham 
Macromolecular Analysis Service as outlined previously [8]. 
Peptides were conjugated to ovalbumin (Sigma) with 
m-maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce 
Chemical Co.) as described by Lee et al. [9]. New Zealand 
White rabbits were injected subcutaneously at two sites with 
peptide-ovalbumin conjugate (100/zg/site) in complete 
Freund's adjuvant. 24 days later animals were injected in the 
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same way with free peptide or with peptide ovalbumin con- 
jugate. Blood was taken from the ear vein at approximately two 
weekly intervals thereafter. 
2.2. Solid-phase immunoassay 
Polystyrene microtitre plates (Dynatech) were coated over- 
night at 4°C with 10/~g/ml histone in phosphate buffered saline 
(PBS). Plates were blocked for 1 h with 1070 bovine serum 
albumin in PBS. Rabbit antiserum, appropriately diluted in 
blocker, was added at 50 ~l/well. After 1 h at 4°C plates were 
washed sequentially with PBS/0.1% Tween 20/1 M NaC1, 
PBS/0.1% Tween 20 and PBS alone. Peroxidase-conjugated 
goat anti-rabbit IgG (Sigma), diluted 1000-fold in blocker, was 
added at 50/zl/well and the plates incubated for 1 h at room 
temperature. Plates were washed twice in PBS/0.1 07o Tween 20 
and four times in distilled water before addition of 100.ul/well 
o-phenylenediamine dihydrochloride solution (0.4 mg/ml in 
24 mM citric acid, 51 mM Na2HPO4, 0.01207o H202, pH5). 
After 10 rain at room temperature the reaction was terminated 
with 100/zl/well 507o H2SO4. Absorbance at 492 nm was read 
on a Multiscan Plus plate reader. Inhibition assays were carried 
out as previously described [8] by mixing varying concentra- 
tions of synthetic peptide with a dilution of antiserum giving 
60-8007o maximum binding. Mixtures were tested against 
histones from butyrate-treated HL60 cells. 
2.3. Cells, histone extraction, electrophoresis and Western 
blotting 
Human promyeloid HL60 cells [10] were grown in RPMI 
1640 medium, 10°70 foetal calf serum in an atmosphere of 5°70 
CO2 in air. Hyperacetylation f histones [11,12] was induced by 
growing the cells for 4-6 h in medium supplemented with 
5-10 mM sodium butyrate (Sigma). Histones were extracted 
from nuclear pellets with 0.2 N HC1 as described previously [8]. 
Sodium butyrate (2 mM) was present throughout the prepara- 
tion procedure. Electrophoresis on acid/urea/Triton gels [13], 
transfer to nitrocellulose filters [14], immunolabeling and scan- 
ning of gels and autoradiographs, were carried out as previously 
described [8]. 
3. RESULTS AND DISCUSSION 
3.1. Preparation of  antisera 
Sixteen rabbits were immunized with synthetic 
peptides corresponding to sequences o f  ten or 
more amino acids in the amino-terminal region 
(1-18) of  histone H4. Peptides contained 
acetyllysine (aK) at all four possible sites (peptide 
PaK4), at a single site (PaK15, etc.) or at none 
(PaK0, see table 1). Thirteen of  the immunized 
animals produced anti-H4 antibodies. The six an- 
tisera used for the experiments described are listed 
in table 1. 
3.2. Characterization of  antibody specificity 
The specificity of  each antiserum for individual 
acetylated sites was tested by measuring the ability 
of  synthetic peptides to inhibit antibody binding to 
histones in a solid-phase immunoassay. Results are 
shown in fig. 1. Animals immunized with peptides 
acetylated at lysines 8, 12 and 16 respectively pro- 
duced anti-histone antibodies which were inhibited 
by the immunizing peptide, but not by other 
mono-acetylated peptides (fig.2A, B and D). In 
contrast, of  the two animals immunized with 
PaK15, one failed to respond while the other (R17) 
produced antibodies which recognised both PaK15 
and PaK l l2 .  (f ig.lC). However, an antiserum 
specific for peptides acetylated at lysine 5 was ob- 
tained by immunization with the tetra-acetylated 
peptide PaK4, as previously described [8]. In what 
follows the antisera will be referred to by numbers 
which define both the particular animal and site 
specificity, i.e. R6/5, R12/8, etc. 
Three of  the site-specific antisera R6/5 [8], 
R20/12 and R14/16 (fig.2B and D) were effectively 
inhibited by PaIG. Thus, binding of  these an- 
tibodies was not influenced by acetylation at adja- 
cent sites, f rom which it can be concluded that the 
epitopes recognised do not incorporate adjacent 
lysine residues (table 1). In contrast, antiserum 
R12/8 was not inhibited by this peptide (fig.2A), 
showing that the antibodies in this serum recognise 
an epitope which requires acetylated lysine 8 
together with lysine 5 and/or  12 in the non- 
acetylated form. 
Thus, the inhibition experiments define both an- 
t ibody specificities and, in some cases, the max- 
imum extent of  the epitopes involved. Our 
conclusions are summarised in table 1. Despite the 
similarity between three of  the four acetylation 
sites (sites 5, 8 and 12 all contain the Gly-Lys-Gly 
tripeptide), all but one of  the sera tested contain 
antibodies directed against a single acetylated site 
and against a narrowly defined epitope. A dual 
specificity was found only in antiserum R17/5,12 
and was confined to the sites at lysines 5 and 12, 
which share the tetrapeptide Gly-Lys-Gly-Gly. 
All four mono-acetylated peptides contain se- 
quences of  five or more amino acids which are 
identical to sequences in non-acetylated H4 (table 
1). The results in f ig. lB and D show that the non- 
acetylated peptide could inhibit binding to HL60 
histones by 10-20°70, suggesting that some sera 
contain antibodies to non-acetylated H4. These 
could be completely removed by absorption with 
immobilised non-acetylated peptide (not shown) 
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Table 1 
Antiserum Immunizing peptide a 
Sequence Name b
Epitope 
Determinan: Extent 
R6/5 
R17/5,12 
R12/8 
R20/12 
R14/16 
R15/0 
1 5 10 15 
AcS GRG* GG* GL G* GGA* RHYC PaK4 
; . • ; 
SGRG*GGKGLYC : PaK~5 
S GRGKGG* GLGKYC:  PaKI18 
: : GKGLG*  GGAKYC PaKal2 
: : GLGKGGA*RHYC PaK~I6 
S GRGKGGKGLGKGGAKRHYC PaK0 
aK5 N-term to G7 
aK5/12 G*GG 
aK8 includes K5 or K12 
aKl2 G9 to A15 
aKl6 G13 to H18 
not known not known 
a Single letter code, for emphasis acetyl lysine (aK) is shown as * 
b These peptides were previously designated Y600, Y632, etc. [8] 
c Antisera bound only to peptides acetylated atthese residues (fig.l) 
and have not proved to be a problem in Western 
blotting experiments, even with non-absorbed 
serum (see below). 
3.3. Site usage in human HL60 cells 
Histones from HL60 cells, either untreated or 
treated with sodium butyrate to induce histone 
hyperacetylation [11,12], were resolved by elec- 
trophoresis on acid/urea/Triton gels and either 
stained with Coomassie blue or transferred to 
nitrocellulose filters and immunostained with site- 
specific antisera. Results are shown in fig.2. 
Antisera raised against the acetylated peptides 
labeled only the acetylated forms of H4 (e.g. 
fig.2A, tracks 3,4). In contrast, R15/0, raised 
against the non-acetylated peptide PaK0, labeled 
H4Aco-2 from both butyrate-treated and untreated 
cells (tracks 5,6) but did not label H4Ac3 and 
H4Ac4. This result is consistent with the inability 
of R15/0 to bind to PaK4 in the inhibition ELISA 
(not shown) and shows that, as might be expected, 
the epitopes recognised by this antiserum are 
masked by acetylation. Labeling of H4 with pre- 
immune serum was insignificant (tracks 7,8). 
In order to ensure complete specificity for only 
a single acetylated site, antisera were routinely pre- 
absorbed with all peptides other than that cor- 
responding to the target acetylation site (see legend 
to fig.2). Antibodies affinity purified on peptide- 
Sepharose columns (unpublished results) were used 
for some experiments (R12/8 and R14/16, fig.2B). 
As an additional test of the specificity of antibody 
labeling, the inhibitory effect of the peptide cor- 
responding to the target acetylation site (i.e. the 
immunizing peptide) was tested for each antiserum 
in the Western blotting-immunostaining assay. 
Scanning of autoradiographs showed that these 
peptides, at concentrations of 1-2/~g/ml, reduced 
antibody binding by at least 90°70. 
The results of immunolabeling H4 from un- 
treated and butyrate-treated cells with pre- 
absorbed antisera to acetylated H4 are shown in 
fig.2B. Only R14/16 (tracks 7,8) gave strong label- 
ing of H4 from untreated cells. These sera labeled 
the mono-acetylated isoform (H4Ac0 more in- 
tensely than the di-acetylated isoform (H4Ac2) and 
gave very weak labeling of H4Ac3. Butyrate treat- 
ment resulted in increased labeling of H4Ac2-4 
(track 7). In contrast, antisera R6/5, R12/8 and 
R20/12 weakly labeled H4AcI from both butyrate- 
treated and untreated cells in comparison with the 
labeling of the more acetylated isoforms. Thus, in 
both butyrate-treated and untreated ceils, most 
H4Act molecules are acetylated at lysine 16, with 
relatively small few acetylated at lysines 5, 8 or 12, 
instead. 
R12/8 labeled H4Ac4 very weakly (fig.2B, track 
3). As all four sites must be acetylated in H4Ac4, 
binding of this antiserum to lysine 8 must be in- 
hibited by acetylation of adjacent sites (i.e. lysines 
143 
Volume 253, number 1,2 FEBS LETTERS August 1989 
II0- 
A 
H1 ~a0- 
H2E 
! , 
1 2 a 4 ..... 5 6 6 .  7 8 
2 3" 1 2 3 4 
PEPTIDE CONC. (uM) 
Fig. 1. Inhibition by synthetic peptides of antibody binding to 
HL60 histones. Antisera tested are as follows: (A) R12/8, (B) 
R14/16, (C) R17/5, (D) R20/12. Inhibiting peptides are 
represented by the following symbols: PaK4 (©), PaK~5 (e), 
PaKt8 (v), PaK]12 (×), PaK~16 (o), PaK0 (m). All four sera 
were tested against all six peptides. Where, for clarity, results 
for a particular peptide are not shown inhibition by that peptide 
was negligible. 
5 and/or  12). This conclusion is entirely consistent 
with the fai lure of  the tetra-acetylated peptide 
PaK4 to inhibit binding of  this ant iserum in EL ISA  
assays (fig. 1). 
The intensity of  labeling of  H4 isoforms re- 
solved on ac id /urea /Tr i ton  gels will depend on the 
concentrat ion of  ant ibody appl ied to the filter, the 
amount  of  each isoform present and the frequency 
with which the site recognised by the ant iserum is 
used in each isoform. It is possible to measure both 
the relative amounts of  protein in the dif ferent H4 
isoforms and the amount  of  ant ibody bound,  by 
scanning Coomassie blue-stained gels and 
autoradiographs,  respectively [8]. Ant ibody  
binding per unit o f  protein can then be calculated. 
This will be directly proport iona l  to the frequency 
with which a part icular  site is used in each 
acetylated isoform. Typical  values are shown in 
fig.3. The results conf i rm the impression gained by 
visual inspection of  autoradiographs,  namely that 
lysine 16 is the most frequently acetylated site in 
H4Ac~, with lower levels of  acetylat ion at lysines 8 
Fig.2. Immunolabeling of HL60 histones separated by 
electrophoresis on acid/urea/Triton gels. Histones were 
extracted from butyrate-treated (1,3,5,7) or untreated (2,4,6,8) 
cells. The number of acetate groups in each H4 isoform is 
indicated (0-4). (Panel A) Tracks: 1,2, total proteins detected 
by Coomassie blue; 3-8, proteins transferred to nitrocellulose 
filters and immunolabeled with R14/16 (3,4), R15/0 (5,6) and 
non-immune serum (7,8). (Panel B) Tracks 1-8, proteins 
transferred to nitrocellulose filters and immunolabeled with 
R6/5 (1,2), affinity purified R12/8 (tracks 3,4), R20/12 (5,6 
and 6A, which is a longer autoradiographic exposure of track 
6), affinity purified R14/16 (7,8). For the experiment shown in 
panel B, sera used for labeling were mixed with synthetic 
peptide PaKo plus 1-2/~g/ml of three of the four mono- 
acetylated peptides hown in table 1, as follows: R6/5 (all 
except PaK15), R12/8 (all except PaK18), R20/12 (all except 
PaKll2), R14/16 (all except PaK, 16). 
z 80- 
o 
60- 
40- 
Z 
----. 20- 
LYS 5 (R6) LYS 8 (R12) LYS 12 (R20) LYS 16 (R14) 
1 2 3 4  1 2 3 4 1 2 3 4 1 2 3 4 
ISOFORMS 
Fig.3. A histogram showing antibody binding (AB) per unit of 
protein to each of the acetylated isoforms of H4 from human 
HL60 cells (numbered 1to 4 on the x-axis). Antibody binding 
was assayed by scanning autoradiographs of immunolabeled 
filters. Autoradiographs u ed for scanning were exposed for 
shorter periods of time than those shown in fig.2, which are 
overexposed to reveal minor bands. 
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and 12 and particularly low usage of the site at 
lysine 5. There is a rapid increase in acetylation at 
lysines 8 and 12 in H4Ac2 and H4Ac3, whereas use 
of lysine 5 increases more slowly, matching that of 
the other acetylation sites only in H4Ac4. 
As outlined elsewhere [8], by expressing an- 
tibody binding per unit protein for each isoform as 
a proportion of binding per unit protein to H4Ac4 
(which should give the maximum possible value), 
one can calculate the proportion of H4 molecules 
in that isoform which are acetylated at each site. 
Thus, from the data presented in fig.3, 60-65°70 of 
all H4Acl molecules are acetylated at lysine 16, 
10-15070 at lysine 12 and only 1-2070 at lysine 5. 
Use of the sites at lysines 12 and 16 increases to 
between 70 and 100070 in H4Ac2 and H4Ac3 
whereas only about 15070 and 4507o, respectively, 
are acetylated at lysine 5. These values are typical 
of several experiments. Such calculations are not 
possible for the site at lysine 8 because of the weak 
binding of R12 to H4Ac4. However, use of this site 
in H4Ac2 and H4Ac3 is clearly much more fre- 
quent than in H4Acl. 
The steady-state frequency of use of each 
acetylation site in H4 is the net result of the actions 
of acetylating and deacetylating enzymes. Thus, 
the fact that most H4Acl molecules in normal cells 
are acetylated at lysine 16, could formally be ex- 
plained by either of two models. (i) Acetylation at 
lysine 16 is usually the first step in the acetylation 
pathway, or (ii) a number of sites can be acetylated 
first, but lysine 16 is relatively resistant o subse- 
quent deacetylation. The second model predicts an 
increase in the use of sites other than lysine 16 after 
inhibition of deacetylases by butyrate. The fact 
that this did not occur (figs 2 and 3), shows that 
acetylation at lysine 16 normally precedes acetyla- 
tion at other sites. Thus, we can conclude that in 
human cells, as H4 molecules move to progressive- 
ly more acetylated forms, the four acetylation sites 
are used in a preferred, but not exclusive order, 
namely lysine 16, followed by lysines 8 and 12, 
followed by lysine 5. 
We have obtained similar results with human 
HL60 cells, HeLa cells and peripheral blood lym- 
phocytes and with Chinese hamster ovary 
fibroblasts. Our findings are also in general agree- 
ment with the amino acid sequencing of mono- 
acetylated calf thymus H4 [7,15], which detected 
acetyilysine at posit ioff l6. The use of H4 acetyla- 
tion sites in mammalian cells is clearly different 
from that in two other experimental systems 
studied to date, namely cuttlefish testis [7] and the 
macronucleus of Tetrahymena [6]. In both these 
organisms ites are used in a strict order, namely 
12, then 5, then 16 for cuttlefish and 7, then 4, then 
11 or 15 for Tetrahymena (which lacks the arginine 
residue at position three of other species [1]). 
Whether these differences are a reflection of evolu- 
tionary distance or the different requirements of 
the tissues involved remains to be established, as 
does the possible functional significance of the 
alternative orders of site usage which appear to be 
possible in at least some human cell types. 
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